ATE236984T1 - Verfahren zur herstellung von hydrophoben polypeptiden, proteinen und peptiden - Google Patents

Verfahren zur herstellung von hydrophoben polypeptiden, proteinen und peptiden

Info

Publication number
ATE236984T1
ATE236984T1 AT94109676T AT94109676T ATE236984T1 AT E236984 T1 ATE236984 T1 AT E236984T1 AT 94109676 T AT94109676 T AT 94109676T AT 94109676 T AT94109676 T AT 94109676T AT E236984 T1 ATE236984 T1 AT E236984T1
Authority
AT
Austria
Prior art keywords
proteins
peptides
hydrophobic polypeptides
producing hydrophobic
purification
Prior art date
Application number
AT94109676T
Other languages
English (en)
Inventor
Heinz Doebeli
Nicholas Draeger
Trottman Gerda Huber
Peter Jakob
Dietrich Stueber
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE236984T1 publication Critical patent/ATE236984T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT94109676T 1993-07-06 1994-06-23 Verfahren zur herstellung von hydrophoben polypeptiden, proteinen und peptiden ATE236984T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP93110755 1993-07-06

Publications (1)

Publication Number Publication Date
ATE236984T1 true ATE236984T1 (de) 2003-04-15

Family

ID=8213046

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94109676T ATE236984T1 (de) 1993-07-06 1994-06-23 Verfahren zur herstellung von hydrophoben polypeptiden, proteinen und peptiden

Country Status (14)

Country Link
US (1) US5750374A (de)
EP (2) EP0641861B1 (de)
JP (2) JP2947401B2 (de)
CN (3) CN1916017A (de)
AT (1) ATE236984T1 (de)
AU (1) AU666274B2 (de)
CA (1) CA2125467C (de)
DE (1) DE69432449T2 (de)
DK (1) DK0641861T3 (de)
ES (1) ES2194017T3 (de)
NZ (1) NZ260907A (de)
PT (1) PT641861E (de)
RU (1) RU94023251A (de)
ZA (1) ZA944686B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303567B1 (en) 1995-03-14 2001-10-16 Praecis Pharmaceuticals, Inc . Modulators of β-amyloid peptide aggregation comprising D-amino acids
US5854204A (en) * 1995-03-14 1998-12-29 Praecis Pharmaceuticals, Inc. Aβ peptides that modulate β-amyloid aggregation
US5817626A (en) * 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US5854215A (en) * 1995-03-14 1998-12-29 Praecis Pharmaceuticals Incorporated Modulators of β-amyloid peptide aggregation
GB9618952D0 (en) 1996-09-11 1996-10-23 Sandoz Ltd Process
US5985242A (en) * 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
US6277826B1 (en) 1996-08-27 2001-08-21 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
NZ514414A (en) 1999-03-04 2004-02-27 Praecis Pharm Inc Modulators of beta-amyloid peptide aggregation comprising D-amino acids
EP1187920A2 (de) 1999-06-09 2002-03-20 Arch Development Corporation Rekombinante prionänhliche gene, proteine, materialien und verfahren davon
CA2387646A1 (en) * 1999-10-21 2001-04-26 Kalobios, Inc. A general method for optimizing the expression of heterologous proteins
US7799561B2 (en) * 2002-06-12 2010-09-21 Sigma-Aldrich, Co. Affinity peptides and method for purification of recombinant proteins
FR2859221B1 (fr) * 2003-08-28 2005-10-14 Centre Nat Rech Scient Vecteur de co-expression de domaines membranaires de proteines d'enveloppe d'un virus et utilisations
US7741053B2 (en) * 2005-05-13 2010-06-22 Sigma-Aldrich Co. Processes for purification of recombinant proteins
KR100621354B1 (ko) * 2005-06-14 2006-09-08 광주과학기술원 유비퀴틴을 이용한 아밀로이드-베타 펩티드의 제조방법
WO2010063460A1 (en) * 2008-12-02 2010-06-10 Universität Zürich Recombinant production of hydrophobic peptides and fusion proteins for use in producing same
EP3199540A4 (de) * 2014-09-26 2018-05-09 Kaneka Corporation Verfahren zur herstellung von hydrophoben peptiden
US10118956B2 (en) 2014-12-01 2018-11-06 Pfenex Inc. Fusion partners for peptide production
CN105001307B (zh) * 2015-07-31 2016-08-24 南京斯拜科生化实业有限公司 一种溶解难溶多肽的偶联肽链及其在液相色谱中分离纯化的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0207044A1 (de) * 1985-06-20 1986-12-30 Monsanto Company Freisetzung von Peptiden aus Polypeptiden
ES2000859A6 (es) * 1985-08-12 1988-03-16 Syntex Inc Un metodo para producir un vector de expresion bacteriana para la expresion de proteinas de fusion
WO1987006005A1 (en) * 1986-03-24 1987-10-08 Ortho Pharmaceutical Corporation Synthetic htlv-iii peptides, compositions and uses thereof
CA1304886C (en) * 1986-07-10 1992-07-07 Heinz Dobeli Metal chelate resins
US5047513A (en) * 1986-07-10 1991-09-10 Hoffmann-La Roche Inc. Metal chelate resins
EP0289110A3 (de) * 1987-02-02 1990-01-24 Swiss Serum and Vaccine Institute Berne Konjugierter Malaria-Impfstoff
CA1340522C (en) * 1987-03-10 1999-05-04 Heinz Dobeli Fusion proteins containing neighbouring histidines for improved purification
US5416007A (en) * 1987-03-20 1995-05-16 Creative Biomolecules, Inc. Enhanced proteolytic cleavage of recombinant fusion proteins
US5124255A (en) * 1988-03-11 1992-06-23 Abbott Laboratories CKS method of protein synthesis
IT1226728B (it) * 1988-08-05 1991-02-05 Eniricerche Spa Coniugato peptidico immunologicamente attivo utile come vaccino antimalaria e metodo di immunizzazione impiegante lo stesso
US5045190A (en) * 1988-11-08 1991-09-03 Carbonell Ruben G Chromatography apparatus
US5387742A (en) * 1990-06-15 1995-02-07 Scios Nova Inc. Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease
WO1992003474A1 (en) * 1990-08-24 1992-03-05 President And Fellows Of Harvard College METHOD OF INTERFERING WITH FORMATION OF α-ANTICHYMOTRYPSIN-β-PROTEIN COMPLEX AND SYNTHETIC PEPTIDES FOR USE THEREIN
EP0484787B1 (de) * 1990-11-03 2001-10-10 Dade Behring Marburg GmbH HCV-spezifische Peptide, Mittel dazu und ihre Verwendung
NZ243636A (en) * 1991-07-29 1993-06-25 Iaf Biochem Int Immunoassay and kit for simultaneously detecting antibodies to hiv-1, hiv-2, htlv-1 and htlv-11
US5434050A (en) * 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease

Also Published As

Publication number Publication date
ES2194017T3 (es) 2003-11-16
RU94023251A (ru) 1996-05-10
ZA944686B (en) 1995-01-06
AU6612294A (en) 1995-01-27
CN1916017A (zh) 2007-02-21
EP0641861A2 (de) 1995-03-08
JP2947401B2 (ja) 1999-09-13
CN1098416A (zh) 1995-02-08
US5750374A (en) 1998-05-12
EP0641861A3 (de) 1997-07-30
CA2125467A1 (en) 1995-01-07
DE69432449T2 (de) 2004-04-08
JPH1143500A (ja) 1999-02-16
EP1304381A3 (de) 2003-05-02
EP0641861B1 (de) 2003-04-09
NZ260907A (en) 1996-06-25
CA2125467C (en) 2001-02-06
PT641861E (pt) 2003-07-31
DK0641861T3 (da) 2003-07-28
AU666274B2 (en) 1996-02-01
CN100439391C (zh) 2008-12-03
CN1057535C (zh) 2000-10-18
JPH07102000A (ja) 1995-04-18
CN1227846A (zh) 1999-09-08
DE69432449D1 (de) 2003-05-15
EP1304381A2 (de) 2003-04-23

Similar Documents

Publication Publication Date Title
ATE236984T1 (de) Verfahren zur herstellung von hydrophoben polypeptiden, proteinen und peptiden
DE69020143D1 (de) Verfahren zur verwendung und herstellung von peptiden.
DE69433934D1 (de) Verfahren und Zusammensetzungen zur erhöhten Proteinproduktion von rekombinanter DNA
DE60041119D1 (de) Verfahren zur präsentation von (poly)peptiden/proteinen auf bakteriophagenpartikeln via disulfidbindungen
DE69122494D1 (de) Vorrichtung zur transdermalen Applikation von Protein- oder Peptid-Medikamenten
DE69019074D1 (de) Verfahren zur Fraktionierung von Plasmaproteinen.
NZ224057A (en) A polypeptide of a vascular anticoagulant protein and method of preparation
ES550943A0 (es) Un procedimiento para preparar una proteina de fusion derivada de la secuencia de aminoacidos de la preprorrelaxina humana.
DE68925275D1 (de) Endotoxin-bindeprotein und dessen verwendung
ES2079621T3 (es) Procedimiento de identificacion o de titulacion de proteinas y aplicaciones.
ES2123582T3 (es) Proteina con capacidad de formacion de huesos y procedimiento para su produccion.
DE69010155D1 (de) Verfahren zur Trennung von Aminosäuren.
ATE189232T1 (de) Protein-s polypeptide und deren verwendungen
ATE139572T1 (de) Verfahren zur reinigung von rekombinanten proteinen und dafür nützliche produkte
DE59702207D1 (de) Verfahren zur eignungsprüfung von faktor viii-haltigen proteinfraktionen
DE59004279D1 (de) Verfahren zur C-terminalen Modifizierung von Proteinen.
DE69328488D1 (de) Peptide, analoge und ihre mischungen zur detektion und erzeugung von antikörpern gegen die e1 und e2 proteine des rubella virus
DE69531955D1 (de) PROGRESSIVE ANDERUNG VON SIGNAL-PROTEINEN UND PEPTIDEn UND DIE HERGESTELLTEN SUPERAGONISTEN UND ANTAGONISTEN
DE69806747D1 (de) Verfahren zur veresterung von aminosäuren und proteinen
DE3485883D1 (de) Rekombinante materialien und verfahren zur herstellung von menschliche konnektive gewebe aktivierende peptide iii und deren analoge.
DE3888078D1 (de) Veränderungsverfahren für Peptide und Proteine.
DE59407615D1 (de) Verfahren zur Herstellung von Peptiden und Verwendung
DE69631054D1 (de) Verfahren zur charakterisierung der feinstruktur von proteinbindungsstellen
ATE79651T1 (de) Rekombinante materialien und verfahren zur herstellung von menschliche konnektive gewebe aktivierende peptide iii und deren analoge.
ATA37288A (de) Verfahren zur auftrennung und reinigung von proteinfraktionen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0641861

Country of ref document: EP

REN Ceased due to non-payment of the annual fee